Do patients with cN0 oral squamous cell carcinoma benefit from elective neck dissection? A large-scale population-based study

医学 颈淋巴结清扫术 比例危险模型 口腔颌面外科 内科学 危险系数 肿瘤科 基底细胞 生存分析 子群分析 外科 置信区间
作者
Qiuyu Wu,Yuanhang Xia,Ling Qiu,Shuqiong Wen,Qunxing Li,Gao Xiang,Wen-Rong Jiang,Tao Wang,Ping Ji,Zhanpeng Ou
出处
期刊:BMC Oral Health [Springer Nature]
卷期号:24 (1)
标识
DOI:10.1186/s12903-023-03632-5
摘要

Abstract Background The neck management of clinical-nodal negative (cN0) oral squamous cell carcinoma (OSCC) remains controversial. Elective neck dissection (END) and observation are the main strategies, but it is still not clear who could benefit the most from END. The purpose of this study was to clarify the potential clinical factors that affect the therapeutic value of END and to explore the actual characteristics associated with benefit from END. Methods Patients with cN0 OSCC were identified in the SEER database from 2000 to 2019. 5-year Overall survival (OS) and disease-specific survival (DSS) were analyzed using the Kaplan‒Meier method, and the hazard ratios (HRs) for survival were estimated using the Cox regression model. Multiple subgroup analyses of DSS and OS among different factors, comparing END and No END, were performed. Results A total of 17,019 patients with cN0 OSCC were included. The basic survival analysis and Cox regression model showed that END increased the probability of 5-year DSS and OS and was an independent prognostic factor. However, among patients who underwent only primary tumor surgery, no significant differences were found between the END and No END groups in 5-year DSS ( P = 0. 585) and OS ( P = 0.465). Further subgroup analysis showed that primary sites and T stage, but not other factors, might influence the benefit of END. Significant differences were found for T1 ( P < 0.001 for OS) and T2 ( P = 0.001 for DSS and < 0.001 for OS) tongue squamous cell carcinoma (TSCC) but not for other primary tumor sites. Conclusion This large-scale retrospective population-based cohort study suggests that not all patients with cN0 OSCC could benefit from END. Patients with cN0 TSCC are recommended to undergo END, especially with early-stage tumors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
adinike发布了新的文献求助10
1秒前
科研通AI6应助愚林2024采纳,获得10
1秒前
科研通AI6应助Fortune采纳,获得10
2秒前
邱乐乐发布了新的文献求助10
2秒前
3秒前
4秒前
量子星尘发布了新的文献求助10
4秒前
李健的小迷弟应助东新采纳,获得10
5秒前
星期天完成签到,获得积分10
6秒前
7秒前
chao完成签到,获得积分10
8秒前
科研通AI6应助JY采纳,获得10
8秒前
笑看小旭旭完成签到,获得积分20
11秒前
幽默书瑶完成签到 ,获得积分10
11秒前
11秒前
成就大白菜真实的钥匙完成签到 ,获得积分10
11秒前
852应助78888采纳,获得10
11秒前
星期天发布了新的文献求助10
11秒前
桐桐应助张瑜采纳,获得10
12秒前
邓茗予完成签到,获得积分20
12秒前
水雾发布了新的文献求助10
12秒前
Lucas应助禹宛白采纳,获得10
13秒前
13秒前
吴先生完成签到,获得积分10
14秒前
14秒前
jin_0124发布了新的文献求助10
14秒前
15秒前
冯雅婷完成签到 ,获得积分10
15秒前
16秒前
16秒前
欣喜谷槐完成签到,获得积分10
16秒前
16秒前
量子星尘发布了新的文献求助10
16秒前
小白鼠完成签到 ,获得积分10
17秒前
18秒前
18秒前
18秒前
科研通AI6应助Fortune采纳,获得10
18秒前
DrLee发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Basic And Clinical Science Course 2025-2026 3000
Encyclopedia of Agriculture and Food Systems Third Edition 2000
人脑智能与人工智能 1000
花の香りの秘密―遺伝子情報から機能性まで 800
Principles of Plasma Discharges and Materials Processing, 3rd Edition 400
Pharmacology for Chemists: Drug Discovery in Context 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5608256
求助须知:如何正确求助?哪些是违规求助? 4692810
关于积分的说明 14875754
捐赠科研通 4717042
什么是DOI,文献DOI怎么找? 2544147
邀请新用户注册赠送积分活动 1509105
关于科研通互助平台的介绍 1472802